Yasuhiro Miki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8913238/publications.pdf

Version: 2024-02-01

126907 155660 3,452 109 33 55 citations h-index g-index papers 110 110 110 4226 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Vasohibin-1 and -2 in pulmonary lymphangioleiomyomatosis (LAM) cells associated with angiogenic and prognostic factors. Pathology Research and Practice, 2022, 230, 153758.	2.3	3
2	Co-expression of nuclear heterogeneous nuclear ribonucleic protein K and estrogen receptor \hat{l}_{\pm} in endometrial cancer. Pathology Research and Practice, 2022, 231, 153795.	2.3	7
3	Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor. Acta Histochemica Et Cytochemica, 2022, 55, 25-35.	1.6	4
4	Appropriate Health Management Considering the Vulnerability of Women during Disasters. Tohoku Journal of Experimental Medicine, 2022, 256, 187-195.	1.2	4
5	B7â€1 and programmed cell deathâ€ligand 1 in primary and lymph node metastasis lesions of nonâ€small cell lung carcinoma. Cancer Medicine, 2022, 11, 479-491.	2.8	5
6	FE65 defines the efficacy of tamoxifen treatment via osteopontin expression in estrogen receptor-positive breast cancer. Pathology Research and Practice, 2022, 234, 153898.	2.3	3
7	Suppression of tumor immune microenvironment via microRNAâ€1 after epidermal growth factor receptorâ€tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma. Cancer Medicine, 2021, 10, 718-727.	2.8	11
8	Stromal CCL5 Promotes Breast Cancer Progression by Interacting with CCR3 in Tumor Cells. International Journal of Molecular Sciences, 2021, 22, 1918.	4.1	16
9	Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen-receptor positive cases. Breast Cancer, 2021, 28, 915-926.	2.9	10
10	Heterogeneous Nuclear Ribonucleoprotein K Is Involved in the Estrogen-Signaling Pathway in Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 2581.	4.1	6
11	Microtubule-Associated Protein 2 as a DHEA Binding Protein in Endometrial Cancer. Journal of the Endocrine Society, 2021, 5, A1026-A1027.	0.2	0
12	Androgens enhance the ability of intratumoral macrophages to promote breast cancer progression. Oncology Reports, 2021, 46, .	2.6	3
13	EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 8522.	4.1	7
14	The Visualization of Protein-Protein Interactions in Breast Cancer: Deployment Study in Pathological Examination. Acta Histochemica Et Cytochemica, 2021, 54, 177-183.	1.6	2
15	D-2-hydroxyglutarate dehydrogenase in breast carcinoma as a potent prognostic marker associated with proliferation. Histology and Histopathology, 2021, , 18362.	0.7	3
16	Aromatase in normal and diseased liver. Hormone Molecular Biology and Clinical Investigation, 2020, 41, .	0.7	4
17	Immunohistochemical assessment of growth factor signaling molecules: MAPK, Akt, and STAT3 pathways in oral epithelial precursor lesions and squamous cell carcinoma. Odontology / the Society of the Nippon Dental University, 2020, 108, 91-101.	1.9	14
18	New Insights into Breast and Endometrial Cancers. Cancers, 2020, 12, 2595.	3.7	7

#	Article	IF	CITATIONS
19	Impact of COVID-19 restrictions on the research environment and motivation of researchers in Japan. Progress in Disaster Science, 2020, 8, 100128.	2.7	21
20	$11\hat{l}^2$ hydroxysteroid dehydrogenase 1: a new marker for predicting response to immune-checkpoint blockade therapy in non-small-cell lung carcinoma. British Journal of Cancer, 2020, 123, 61-71.	6.4	6
21	Vasohibinâ€1 and miRâ€720 expression in diffuse pulmonary capillary hemangiomatosisâ€ike changes associated with pulmonary hypoplasia. Pathology International, 2020, 70, 470-472.	1.3	2
22	Cervical cancer screening rates before and after the Great East Japan Earthquake in the Miyagi Prefecture, Japan. PLoS ONE, 2020, 15, e0229924.	2.5	8
23	Rac1 activation in human breast carcinoma as a prognostic factor associated with therapeutic resistance. Breast Cancer, 2020, 27, 919-928.	2.9	13
24	Significance of glucocorticoid signaling in triple-negative breast cancer patients: a newly revealed interaction with androgen signaling. Breast Cancer Research and Treatment, 2020, 180, 97-110.	2.5	16
25	Title is missing!. , 2020, 15, e0229924.		0
26	Title is missing!. , 2020, 15, e0229924.		0
27	Title is missing!. , 2020, 15, e0229924.		0
28	Title is missing!. , 2020, 15, e0229924.		0
29	Title is missing!. , 2020, 15, e0229924.		0
30	Title is missing!. , 2020, 15, e0229924.		0
31	The significance of lipid accumulation in breast carcinoma cells through perilipin 2 and its clinicopathological significance. Pathology International, 2019, 69, 463-471.	1.3	17
32	PD-L1 Induction by Cancer-Associated Fibroblast-Derived Factors in Lung Adenocarcinoma Cells. Cancers, 2019, 11, 1257.	3.7	52
33	Prognostic significance of combining immunohistochemical markers for cancer-associated fibroblasts in lung adenocarcinoma tissue. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 181-189.	2.8	9
34	Co-expression of carcinoembryonic antigen-related cell adhesion molecule 6 and 8 inhibits proliferation and invasiveness of breast carcinoma cells. Clinical and Experimental Metastasis, 2019, 36, 423-432.	3.3	11
35	Amyloid precursor protein and its phosphorylated form in non-small cell lung carcinoma. Pathology Research and Practice, 2019, 215, 152463.	2.3	8
36	Multiple primary cancers associated with endometrial and ovarian cancers: An analysis based upon the Japan Autopsy Annual Database from 2002 to 2010. Journal of Obstetrics and Gynaecology Research, 2019, 45, 1012-1018.	1.3	2

#	Article	IF	Citations
37	S100P and Ezrin promote trans-endothelial migration of triple negative breast cancer cells. Cellular Oncology (Dordrecht), 2019, 42, 67-80.	4.4	33
38	Cytochrome c1 as a favorable prognostic marker in estrogen receptor-positive breast carcinoma. Histology and Histopathology, 2019, 34, 1365-1375.	0.7	4
39	Tumor microenvironment in functional adrenocortical adenomas: immune cell infiltration in cortisol-producing adrenocortical adenoma. Human Pathology, 2018, 77, 88-97.	2.0	16
40	The interplay of endocrine therapy, steroid pathways and therapeutic resistance: Importance of androgen in breast carcinoma. Molecular and Cellular Endocrinology, 2018, 466, 31-37.	3.2	10
41	Exploring Protein–Protein Interaction in the Study of Hormone-Dependent Cancers. International Journal of Molecular Sciences, 2018, 19, 3173.	4.1	19
42	The interaction between carcinoembryonic antigenâ€related cell adhesion molecule 6 and human epidermal growth factor receptor 2 is associated with therapeutic efficacy of trastuzumab in breast cancer. Journal of Pathology, 2018, 246, 379-389.	4.5	5
43	The Significance of MMP-1 in EGFR-TKl–Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting. International Journal of Molecular Sciences, 2018, 19, 609.	4.1	21
44	$17\hat{l}^2$ -Hydroxysteroid Dehydrogenase Type 2 Expression Is Induced by Androgen Signaling in Endometrial Cancer. International Journal of Molecular Sciences, 2018, 19, 1139.	4.1	13
45	Roles of human epidermal growth factor receptor family in pulmonary lymphangioleiomyomatosis. Human Pathology, 2018, 81, 121-130.	2.0	2
46	Relaxin 2/RXFP1 Signaling Induces Cell Invasion via the \hat{I}^2 -Catenin Pathway in Endometrial Cancer. International Journal of Molecular Sciences, 2018, 19, 2438.	4.1	18
47	ARHGAP15 in Human Breast Carcinoma: A Potent Tumor Suppressor Regulated by Androgens. International Journal of Molecular Sciences, 2018, 19, 804.	4.1	16
48	In situ detection of estrogen receptor dimers in breast carcinoma cells in archival materials using proximity ligation assay (PLA). Journal of Steroid Biochemistry and Molecular Biology, 2017, 165, 159-169.	2.5	22
49	Aryl hydrocarbon receptor induced intratumoral aromatase in breast cancer. Breast Cancer Research and Treatment, 2017, 161, 399-407.	2.5	16
50	Effects of cytokines derived from cancer-associated fibroblasts on androgen synthetic enzymes in estrogen receptor-negative breast carcinoma. Breast Cancer Research and Treatment, 2017, 166, 709-723.	2.5	13
51	<i>In Situ</i> Evaluation of Estrogen Receptor Dimers in Breast Carcinoma Cells: Visualization of Protein-Protein Interactions. Acta Histochemica Et Cytochemica, 2017, 50, 85-93.	1.6	13
52	Roles of Aryl Hydrocarbon Receptor in Aromatase-Dependent Cell Proliferation in Human Osteoblasts. International Journal of Molecular Sciences, 2017, 18, 2159.	4.1	19
53	In situ androgen and estrogen biosynthesis in endometrial cancer: focus on androgen actions and intratumoral production. Endocrine-Related Cancer, 2016, 23, R323-R335.	3.1	24
54	Analysis of multiple primary cancer autopsy cases associated with breast cancer: 2002–2010. Pathology International, 2016, 66, 695-700.	1.3	3

#	Article	IF	CITATIONS
55	Steroid and xenobiotic receptor-mediated effects of bisphenol A on human osteoblasts. Life Sciences, 2016, 155, 29-35.	4.3	17
56	Intratumoral estrogen production and actions in luminal A type invasive lobular and ductal carcinomas. Breast Cancer Research and Treatment, 2016, 156, 45-55.	2.5	8
57	Tumor microenvironment in invasive lobular carcinoma: possible therapeutic targets. Breast Cancer Research and Treatment, 2016, 155, 65-75.	2.5	30
58	The role of 5α-reductase type 1 associated with intratumoral dihydrotestosterone concentrations in human endometrial carcinoma. Molecular and Cellular Endocrinology, 2015, 401, 56-64.	3.2	32
59	An activation of <scp>LC3A</scp> â€mediated autophagy contributes to <i>de novo</i> and acquired resistance to <scp>EGFR</scp> tyrosine kinase inhibitors in lung adenocarcinoma. Journal of Pathology, 2014, 234, 277-288.	4.5	44
60	NRF2 immunolocalization in human breast cancer patients as a prognostic factor. Endocrine-Related Cancer, 2014, 21, 241-252.	3.1	55
61	Aryl Hydrocarbon Receptor in Breast Cancer—A Newly Defined Prognostic Marker. Hormones and Cancer, 2014, 5, 11-21.	4.9	32
62	Tissue concentrations of estrogens and aromatase immunolocalization in interstitial pneumonia of human lung. Molecular and Cellular Endocrinology, 2014, 392, 136-143.	3.2	12
63	Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast. Cancer Science, 2014, 105, 1503-1509.	3.9	9
64	Androgen and androgen-metabolizing enzymes in metastasized lymph nodes of breast cancer. Human Pathology, 2013, 44, 2338-2345.	2.0	12
65	Distinct nuclear receptor expression in stroma adjacent to breast tumors. Breast Cancer Research and Treatment, 2013, 142, 211-223.	2.5	45
66	Immunohistochemical analysis of aromatase in metastatic lymph nodes of breast cancer. Pathology International, 2013, 63, 20-28.	1.3	5
67	Androgenic pathway in triple negative invasive ductal tumors: Its correlation with tumor cell proliferation. Cancer Science, 2013, 104, 639-646.	3.9	71
68	Hexokinase <scp>II</scp> in breast carcinoma: A potent prognostic factor associated with hypoxiaâ€inducible factorâ€1α and <scp>K</scp> iâ€67. Cancer Science, 2013, 104, 1380-1388.	3.9	59
69	Assessment of protein expression and gene status of human epidermal growth factor receptor (<scp>HER</scp>) family molecules in ameloblastomas. Journal of Oral Pathology and Medicine, 2013, 42, 424-434.	2.7	18
70	The advantages of co-culture over mono cell culture in simulating in vivo environment. Journal of Steroid Biochemistry and Molecular Biology, 2012, 131, 68-75.	2.5	143
71	An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma. Journal of Translational Medicine, 2012, 10, S2.	4.4	32
72	Steroid sulfatase and estrogen sulfotransferase in human carcinomas. Molecular and Cellular Endocrinology, 2011, 340, 148-153.	3.2	36

#	Article	IF	CITATIONS
73	The role of estrogen-metabolizing enzymes and estrogen receptors in human epidermis. Molecular and Cellular Endocrinology, 2011, 344, 35-40.	3.2	26
74	Androgens in human breast carcinoma. Medical Molecular Morphology, 2010, 43, 75-81.	1.0	36
75	Steroid and xenobiotic receptor in human esophageal squamous cell carcinoma: A potent prognostic factor. Cancer Science, 2010, 101, 543-549.	3.9	19
76	Immunolocalization of estrogenâ€producing and metabolizing enzymes in benign breast disease: Comparison with normal breast and breast carcinoma. Cancer Science, 2010, 101, 2286-2292.	3.9	23
77	Runx2 in human breast carcinoma: its potential roles in cancer progression. Cancer Science, 2010, 101, 2670-2675.	3.9	68
78	Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment. Endocrine-Related Cancer, 2010, 17, 415-430.	3.1	64
79	Intratumoral Localization of Aromatase and Interaction between Stromal and Parenchymal Cells in the Non–Small Cell Lung Carcinoma Microenvironment. Cancer Research, 2010, 70, 6659-6669.	0.9	49
80	$17\hat{l}^2$ -Hydroxysteroid Dehydrogenase Type 12 in Human Breast Carcinoma: A Prognostic Factor via Potential Regulation of Fatty Acid Synthesis. Cancer Research, 2009, 69, 1392-1399.	0.9	36
81	Steroid Sulfatase and Estrogen Sulfotransferase in Colon Carcinoma: Regulators of Intratumoral Estrogen Concentrations and Potent Prognostic Factors. Cancer Research, 2009, 69, 914-922.	0.9	56
82	Local Biosynthesis of Estrogen in Human Endometrial Carcinoma through Tumor-Stromal Cell Interactions. Clinical Cancer Research, 2009, 15, 6028-6034.	7.0	22
83	<i>ln situ</i> estrogen production and its regulation in human breast carcinoma: From endocrinology to intracrinology. Pathology International, 2009, 59, 777-789.	1.3	80
84	Aromatase expression and outcomes in the PO24 neoadjuvant endocrine therapy trial. Breast Cancer Research and Treatment, 2009, 116, 371-378.	2.5	38
85	Intracrinology of sex steroids in ductal carcinoma in situ (DCIS) of human breast: Comparison to invasive ductal carcinoma (IDC) and non-neoplastic breast. Journal of Steroid Biochemistry and Molecular Biology, 2009, 114, 68-71.	2.5	19
86	Comparative effects of raloxifene, tamoxifen and estradiol on human osteoblasts in vitro: Estrogen receptor dependent or independent pathways of raloxifene. Journal of Steroid Biochemistry and Molecular Biology, 2009, 113, 281-289.	2.5	26
87	Intratumoral estrogen production in breast carcinoma: significance of aromatase. Breast Cancer, 2008, 15, 270-277.	2.9	28
88	Sex steroid receptors expression and hormoneâ€induced cell proliferation in human osteosarcoma. Cancer Science, 2008, 99, 518-523.	3.9	44
89	Intracrinology of estrogens and androgens in breast carcinoma. Journal of Steroid Biochemistry and Molecular Biology, 2008, 108, 181-185.	2,5	73
90	Intratumoral Estrogens and Estrogen Receptors in Human Non–Small Cell Lung Carcinoma. Clinical Cancer Research, 2008, 14, 4417-4426.	7.0	179

#	Article	IF	CITATIONS
91	Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. Endocrine-Related Cancer, 2008, 15, 113-124.	3.1	70
92	Aromatase in Human Breast Carcinoma as a Key Regulator of Intratumoral Sex Steroid Concentrations. Endocrine Journal, 2008, 55, 455-463.	1.6	32
93	New development in intracrinology of breast carcinoma: therapeutic horizons after aromatase inhibitors. Expert Review of Endocrinology and Metabolism, 2007, 2, 367-374.	2.4	0
94	Aromatase Localization in Human Breast Cancer Tissues: Possible Interactions between Intratumoral Stromal and Parenchymal Cells. Cancer Research, 2007, 67, 3945-3954.	0.9	117
95	Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: A possible androgenic bone protective effects induced by exemestane. Bone, 2007, 40, 876-887.	2.9	46
96	Controversies of aromatase localization in human breast cancerâ€"Stromal versus parenchymal cells. Journal of Steroid Biochemistry and Molecular Biology, 2007, 106, 97-101.	2.5	27
97	$5\hat{l}\pm$ -Reductase type 1 and aromatase in breast carcinoma as regulators ofin situ androgen production. International Journal of Cancer, 2007, 120, 285-291.	5.1	71
98	In situ production of sex steroids in human breast carcinoma. Medical Molecular Morphology, 2007, 40, 121-127.	1.0	34
99	Immunolocalization of liver receptor homologue-1 (LRH-1) in human breast carcinoma: Possible regulator of in situ steroidogenesis. Cancer Letters, 2006, 244, 24-33.	7.2	52
100	Expression of the Steroid and Xenobiotic Receptor and Its Possible Target Gene, Organic Anion Transporting Polypeptide-A, in Human Breast Carcinoma. Cancer Research, 2006, 66, 535-542.	0.9	132
101	Analysis for Localization of Steroid Sulfatase in Human Tissues. Methods in Enzymology, 2005, 400, 303-316.	1.0	9
102	Sex steroid-producing enzymes in human breast cancer. Endocrine-Related Cancer, 2005, 12, 701-720.	3.1	156
103	Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues. Molecular and Cellular Endocrinology, 2005, 231, 75-85.	3.2	133
104	Analysis of gene expression induced by diethylstilbestrol (DES) in human primitive $M\tilde{A}^{1/4}$ llerian duct cells using microarray. Cancer Letters, 2005, 220, 197-210.	7.2	10
105	Interactions between prostaglandin E(2), liver receptor homologue-1, and aromatase in breast cancer. Cancer Research, 2005, 65, 657-63.	0.9	7 5
106	Sex steroid receptors in rheumatoid arthritis. Clinical Science, 2004, 106, 293-300.	4.3	59
107	Steroid Sulfatase and Estrogen Sulfotransferase in the Atherosclerotic Human Aorta. American Journal of Pathology, 2003, 163, 1329-1339.	3.8	40
108	Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Research, 2003, 63, 2762-70.	0.9	146

#	Article	IF	CITATIONS
109	Systemic Distribution of Steroid Sulfatase and Estrogen Sulfotransferase in Human Adult and Fetal Tissues. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5760-5768.	3.6	156